| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06d114257182ee7efd4c696c5fdb836
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3662ce5995dada5ea3d9873552592af0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2009-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f83380ac0ad0f66e0572056e0dbb1713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecf9ec796a3139d32c528efa2a3288e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da843dbe5269ce1bbf93b1765a8337a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ef00f11e904960f38a9be6c2a6d23cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35024c937b3309098654236eba771d1d |
| publicationDate |
2015-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2529593-T3 |
| titleOfInvention |
Disease markers and their uses |
| abstract |
Method for monitoring the progression of myositis in a patient receiving treatment with a therapeutic agent, comprising: (i) obtaining a first expression profile of IFNa-inducible PD marker in a first patient sample, (ii) obtaining a second IFNa-inducible PD marker expression profile in a second patient sample after a therapeutic agent has been administered, and (iii) compare the first and second IFNa-inducible PD marker expression profiles; wherein the IFNa inducible PD marker expression profile is based on upregulation of expression of the following genes IFI27, IFI44, IFI44L and RSA02; and in which a variance in the first and second expression profiles of IFNa inducible PD marker indicates a level of efficacy of the therapeutic agent, in which the variance is a decrease in expression regulated by an increase in the gene. |
| priorityDate |
2008-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |